



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Lalruatadika Varte, Drugs Inspector
Office of the Chief Medical Officer
Kolasib, Mizoram- 796082
2. Serial No. and date of Inspector's memorandum : 002/IPA-KLB/III-2025 , 05-JUN-2025
3. Number of Sample : NIL
4. Date of receipt : 26-JUN-2025
5. Names of drugs purporting to be contained in the sample : Cetirizine Tablets I.P. 10 mg

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/1010	GUW/LS/2025-26/1001	Z24-1076	Dec-2024 Nov-2026	NA	M/s. ZEE LABORATORIES LTD Behind 47, Industrial Area, Paonta Sahib-173025

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 26-Nov-2025 To 01-Dec-2025

COMPOSITION : Each film coated tablet contains: Cetirizine Hydrochloride IP 10 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, elongated, slightly biconvex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Cetirizine Hydrochloride.	NA
3	Average weight	0.1445 g	NA
4	Test for Dissolution	Complies.	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Cetirizine Hydrochloride	9.66 mg/Tablet	10 mg/Tablet	96.6	90 % to 110 %	I.P. 2022

the opinion of the undersigned the sample referred to above is of standard quality as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 16-DEC-2025

Rinku Kalita
GOVERNMENT ANALYST

/ Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

END OF REPORT